Inside SimBioSys TumorSight Risk: Bringing Recurrence Assessment Into the MRI Workflow
Dr. Dereck Mush, MD, MBA
Sponsored by
State of Product reveals what AI still hasn’t solved
80% of product professionals say AI helps them ship faster, but customers aren’t seeing value any sooner. Atlassian’s State of Product 2027 explores the gains AI is delivering and the challenges that remain, from decision-making that hasn’t kept pace to gut instinct overriding customer evidence.
PRECISION ONCOLOGY
1. SimBioSys Secures FDA 510(k) Clearance for TumorSight Risk
SimBioSys visualises tumour structure to support its approach to precision breast cancer care. Image: SimBioSys.
The FDA has granted 510(k) clearance (K260023) to SimBioSys for TumorSight Risk, the world's first AI-powered, MRI-derived prognostic tool that estimates 5- and 10-year recurrence-free survival in patients with HR-positive, HER2-negative stage I to IIIA breast cancer.
The details:
In multi-center clinical validation cohorts, patients stratified into the high-risk category demonstrated a hazard ratio of 2.81 for disease recurrence compared to low-risk cohorts.
Built on the FDA-cleared TumorSight Viz platform, the software extracts 3D biophysical tumor phenotyping, peritumoral parenchymal architecture, and spatial cellular density directly from standard-of-care dynamic contrast-enhanced MRI without requiring additional surgical tissue destruction.
The clearance gives multidisciplinary tumor boards an actionable prognostic risk score at the pre-surgical planning phase, bridging non-invasive imaging with longitudinal therapeutic stratification.
The Signal: TumorSight Risk breaks the long-standing dependency on postoperative genomic assays (such as Oncotype DX and MammaPrint) by delivering equivalent prognostic stratification directly from pre-operative MRI scans. By moving risk assessment upstream from surgical pathology to diagnostic radiology, health systems can eliminate two-to-four-week genomic testing turnarounds, reduce tissue sample consumption, and personalize neoadjuvant treatment strategies before the first surgical incision is made.
AMBIENT CARE & POST-ACUTE AI
2. Doximity Integrates UpToDate Directly into Point-of-Care Clinical AI
Doximity and Wolters Kluwer are bringing UpToDate’s clinical content into Doximity Ask. Image: Doximity/Wolters Kluwer.
Doximity announced a native clinical integration embedding Wolters Kluwer's UpToDate evidence synthesis directly into its HIPAA-compliant generative clinical workflow engine across its network of over 2 million verified US medical professionals.
The details:
The system combines conversational chart summarization and patient communication drafts with real-time, peer-reviewed clinical monographs, dynamically grounding generative AI responses in verified medical literature.
Clinicians can surface graded treatment recommendations, drug interaction checks, and diagnostic algorithms inside their active mobile or desktop workflow without toggling between separate browser tabs or external reference portals.
The architecture enforces strict citation attribution, linking every generated clinical recommendation directly to specific UpToDate evidence topics and source literature to mitigate LLM hallucination in high-stakes clinical decision-making.
The Signal: Point-of-care clinical AI is pivoting from unstructured generalist LLMs to strictly bounded, authoritative evidence retrieval. By pairing its verified physician graph with healthcare's gold-standard clinical reference database, Doximity is building a defensible moat against horizontal AI giants, proving that clinical utility in medicine depends less on parameter scale and more on deterministic clinical authority.
MANAGED CARE
3. Even Healthcare Lands $50M Series B Led by Khosla Ventures
Even Healthcare’s founding team, pictured in an archive company image. Image: Even Healthcare.
Even Healthcare, an integrated managed care and hospital provider headquartered in Bengaluru, closed a $50 million Series B round led by Khosla Ventures with participation from Alpha Wave and existing institutional backers.
The details:
The fresh capital will accelerate the expansion of Even's owned outpatient clinic network and scale its proprietary vertically integrated payer-provider model across major metropolitan hubs.
Unlike traditional third-party insurance administrators that operate on transactional fee-for-service reimbursement, Even bundles unlimited primary care consultations, preventive diagnostics, and inpatient hospitalization coverage under a single managed subscription.
The company's clinical operating model leverages automated triage algorithms and primary care gatekeeping to reduce avoidable secondary hospitalizations by over 30%, aligning health system incentives directly with patient outcomes.
The Signal: Even Healthcare represents the global exportation of the Kaiser Permanente managed care playbook into high-growth emerging markets plagued by fragmented fee-for-service hospital billing. By owning both the clinical delivery points and the underlying underwriting risk, vertically integrated digital health systems can dismantle perverse volume incentives, proving that the ultimate margin moat in healthcare lies in primary care gatekeeping rather than tertiary bed occupancy.
Related reading
Dr. Dereck Mush, MD, MBA
Inside TumorSight Risk: What MRI-Based Recurrence Assessment Can and Cannot Tell Clinicians
Dr. Dereck Mush, MD, MBA
The MCED Inflection Point: What Galleri's FDA Panel Backing Means for Cancer Screening
Dr. Dereck Mush, MD, MBA
The Post-Aromatase Battlefield: Breaking Down Eli Lilly's Inluriyo Strategy, Companion Diagnostic Moats, and the Oral SERD Market Shift
Dr. Dereck Mush, MD, MBAKeep exploring